Hikma Pharmaceuticals Regulatory News (HIK)

Board Appointment - Dr Pamela Kirby

London, 6 November 2014 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (OTC: HKMPY) ("Hikma"), the FTSE 250 pharmaceuticals company, is today announcing the appointment of Dr Pamela Kirby as an independent non-executive director of the Company with effect from 1 December 2014. Dr Kirby will join the Audit, Remuneration and Compliance, Responsibility and Ethics (CRE) Committees.

Said Darwazah, Chairman and Chief Executive, said: "I am delighted that Dr Kirby has agreed to join our Board. She brings a wealth of pharmaceutical, international, strategic, and listed company experience. She has a strong track record from her senior executive and board-level roles, and complements our culture and style perfectly. I am confident that she will enhance the capabilities of the Board, and that we are now in an even stronger position to lead our company going forward."

Dr Pamela Kirby

Dr Pamela Kirby was CEO of Quintiles Transnational Corp and has held senior executive positions in F Hoffmann-La Roche Ltd and AstraZeneca plc. Dr Kirby has chaired Oxford Immunotec Ltd and was senior independent director of Informa plc. Dr Kirby has previously held non-executive director positions with Smith & Nephew plc, Novo Nordisk A/S, Curalogic A/S and Oscient Pharmaceuticals Corp.

Dr Kirby is chairman of Scynexis Inc and a non-executive director of DCC plc and Victrex plc.

Dr Kirby holds a first-class Bachelor of Science degree in Pharmacology and a PhD in Clinical Pharmacology from the University of London.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC

Peter Speirs, Company Secretary +44 (0)20 7399 2772

Susan Ringdal, Vice President for Investor Relations +44 (0)20 7399 2760

Financial Dynamics +44 (0)20 3727 1000

Matthew Cole & Ben Atwell

Notes to Editors:

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.